Fox Run Management L.l.c. adds Amgen (AMGN) to its portfolio

Amgen (AMGN) : Fox Run Management L.l.c. added new position in Amgen during the most recent quarter end. The investment management firm now holds 5,800 shares of Amgen which is valued at $946,850 , the company said in a statement filed on Jul 18, 2016 with the SEC.Amgen makes up approximately 0.44% of Fox Run Management L.l.c.’s portfolio.

Other Hedge Funds, Including , Simplex Trading reduced its stake in AMGN by selling 6,632 shares or 19.33% in the most recent quarter. The Hedge Fund company now holds 27,673 shares of AMGN which is valued at $4,517,617. Amgen makes up approx 0.57% of Simplex Trading’s portfolio.Trust Department Mb Financial Bank N A reduced its stake in AMGN by selling 80 shares or 10.01% in the most recent quarter. The Hedge Fund company now holds 719 shares of AMGN which is valued at $117,147. Amgen makes up approx 0.01% of Trust Department Mb Financial Bank N A’s portfolio.First Western Capital Management Co reduced its stake in AMGN by selling 159 shares or 1.54% in the most recent quarter. The Hedge Fund company now holds 10,186 shares of AMGN which is valued at $1,635,057. Amgen makes up approx 0.58% of First Western Capital Management Co’s portfolio.Gateway Investment Advisers reduced its stake in AMGN by selling 6,545 shares or 1.25% in the most recent quarter. The Hedge Fund company now holds 517,128 shares of AMGN which is valued at $83,009,387. Amgen makes up approx 0.70% of Gateway Investment Advisers’s portfolio.

Amgen opened for trading at $162.45 and hit $163.65 on the upside on Wednesday, eventually ending the session at $163.25, with a gain of 0.47% or 0.76 points. The heightened volatility saw the trading volume jump to 21,61,425 shares. Company has a market cap of $122,636 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *